Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer

Oncologist. 2017 Oct;22(10):1281. doi: 10.1634/theoncologist.2016-0133erratum.
No abstract available

Publication types

  • Published Erratum